Literature DB >> 25908255

Multitarget intervention of Fasudil in the neuroprotection of dopaminergic neurons in MPTP-mouse model of Parkinson's disease.

Yong-fei Zhao1, Qiong Zhang2, Jian-ying Xi3, Yan-hua Li4, Cun-gen Ma5, Bao-guo Xiao6.   

Abstract

Recent studies have demonstrated that activation of the Rho-associated kinase (ROCK) pathway participates in the dopaminergic neuron degeneration and possibly in Parkinson's disease (PD). In the current study, we tried to observe the therapeutic potential of ROCK inhibitor Fasudil against dopaminergic neuron injury in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-mouse model of PD, and explore possible molecular mechanisms by enzyme-linked immunosorbent assay (ELISA), western blot and immunofluorescent assays. The results showed that MPTP-PD mice presented motor deficits, dopaminergic neuron loss, activation of inflammatory response and oxidative stress as well as ROCK and glycogen synthase kinase 3β (GSK-3β) signaling pathways. The administration of Fasudil exhibited neuroprotective effects against the dopaminergic neurons and improved the motor function recovery in the MPTP-PD mice, accompanied by the suppression of inflammatory responses (IL-1β, TNF-α, NF-κB-p65 and TLR-2), and oxidative stress (iNOS and gp91Phox), which might be associated with the inhibition of ROCK and GSK-3β activity. Simultaneously, the administration of Fasudil resulted in the shift from inflammatory M1 to anti-inflammatory/neurorepair M2 microglia. Additionally, Fasudil intervention enhanced the expression of anti-oxidative factors such as NF-E2-related factor 2 (Nrf2), Hmox as well as neurotrophic factor including GDNF. Our observations defined the neuroprotective effects of Fasudil in MPTP-PD mice, and we found a series of novel effector molecules and pathways for explaining the neuroprotective effects against dopaminergic neurons. However, a lot of investigations are warranted to further elucidate the crosstalk among Fasudil, oxidative stress, inflammatory response, GDNF and ROCK/NF-kB/Nrf2 pathways in the therapeutic potential of PD.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  1-Methyl-4-phenyl-1,-2,3,6-tetrahydropyridine (MPTP); Dopaminergic neurons; Fasudil; Neuroprotection; Parkinson's disease (PD); Rho kinase inhibitor

Mesh:

Substances:

Year:  2015        PMID: 25908255     DOI: 10.1016/j.jns.2015.03.022

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  19 in total

1.  L-F001, a Multifunction ROCK Inhibitor Prevents 6-OHDA Induced Cell Death Through Activating Akt/GSK-3beta and Nrf2/HO-1 Signaling Pathway in PC12 Cells and Attenuates MPTP-Induced Dopamine Neuron Toxicity in Mice.

Authors:  Liting Luo; Jingkao Chen; Dan Su; Meihui Chen; Bingling Luo; Rongbiao Pi; Lan Wang; Wei Shen; Rikang Wang
Journal:  Neurochem Res       Date:  2017-01-11       Impact factor: 3.996

2.  Fasudil Enhances Therapeutic Efficacy of Neural Stem Cells in the Mouse Model of MPTP-Induced Parkinson's Disease.

Authors:  Yan-Hua Li; Jing-Wen Yu; Jian-Yin Xi; Wen-Bo Yu; Jian-Chun Liu; Qing Wang; Li-Juan Song; Ling Feng; Ya-Ping Yan; Guang-Xian Zhang; Bao-Guo Xiao; Cun-Gen Ma
Journal:  Mol Neurobiol       Date:  2016-09-02       Impact factor: 5.590

Review 3.  Nrf2--a therapeutic target for the treatment of neurodegenerative diseases.

Authors:  Delinda A Johnson; Jeffrey A Johnson
Journal:  Free Radic Biol Med       Date:  2015-08-14       Impact factor: 7.376

4.  Oligophrenin-1 moderates behavioral responses to stress by regulating parvalbumin interneuron activity in the medial prefrontal cortex.

Authors:  Minghui Wang; Nicholas B Gallo; Yilin Tai; Bo Li; Linda Van Aelst
Journal:  Neuron       Date:  2021-04-07       Impact factor: 18.688

5.  Rho Kinase Inhibition with Fasudil in the SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis-Symptomatic Treatment Potential after Disease Onset.

Authors:  René Günther; Alexander Balck; Jan C Koch; Tobias Nientiedt; Michael Sereda; Mathias Bähr; Paul Lingor; Lars Tönges
Journal:  Front Pharmacol       Date:  2017-01-31       Impact factor: 5.810

Review 6.  Modulation of Microglial Activity by Rho-Kinase (ROCK) Inhibition as Therapeutic Strategy in Parkinson's Disease and Amyotrophic Lateral Sclerosis.

Authors:  Anna-Elisa Roser; Lars Tönges; Paul Lingor
Journal:  Front Aging Neurosci       Date:  2017-04-04       Impact factor: 5.750

Review 7.  Toll-Like Receptor 2 Signaling and Current Approaches for Therapeutic Modulation in Synucleinopathies.

Authors:  Ian F Caplan; Kathleen A Maguire-Zeiss
Journal:  Front Pharmacol       Date:  2018-05-04       Impact factor: 5.810

8.  Nrf2 and NF-κB Signaling Pathways Contribute to Porphyra-334-Mediated Inhibition of UVA-Induced Inflammation in Skin Fibroblasts.

Authors:  Jina Ryu; Mi-Jin Kwon; Taek-Jeong Nam
Journal:  Mar Drugs       Date:  2015-07-31       Impact factor: 5.118

Review 9.  Non-muscle myosin II in disease: mechanisms and therapeutic opportunities.

Authors:  Karen A Newell-Litwa; Rick Horwitz; Marcelo L Lamers
Journal:  Dis Model Mech       Date:  2015-11-05       Impact factor: 5.758

10.  Propionic Acid and Fasudil as Treatment Against Rotenone Toxicity in an In Vitro Model of Parkinson's Disease.

Authors:  Friederike Ostendorf; Judith Metzdorf; Ralf Gold; Aiden Haghikia; Lars Tönges
Journal:  Molecules       Date:  2020-05-28       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.